1. 1. Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes.implications for therapy. Diabetes 2010. 59:2697-707. doi: 10.2337/db10-1032 2. 2. Riserus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Prog Lipid Res 2009; 48:44-51. doi: 10.1016/j.plipres.2008.10.002 3. 3. van 't Riet E. Role of adiposity and lifestyle in the relationship between family history of diabetes and 20-year incidence of type 2 diabetes in U.S. women. Diabetes Care 2010; 33:763-7. doi: 10.2337/dc09-1586 4. 4. Yoon PW, Scheuner MT, Khoury MJ. Research priorities for evaluating family history in the prevention of common chronic diseases. Am J Prev Med 2003; 24: 128-35. DOI: 10.1016/s0749-3797(02)00585-8 5. 5. Melmed S. Williams textbook of endocrinology.ed. t. Edition. 2011; ISBN:9781437736007 6. 6. Nasiri M. Association of G-2548A polymorphism in the promoter of leptin gene with plasma leptin level and risk of type 2 diabetes. J Kerman Uni Med Sci 2013; 4: 70-77. 7. 7. Fuchsberger C. The genetic architecture of type 2 diabetes. Nature 2016; 536:41-47. doi: 10.1038/nature18642 8. 8. Gaulton KJ. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet 2015; 47:1415-25. doi: 10.1038/ng.3437 9. 9. Wellen KE, Hotamisligil GS. Inflammation, stress and diabetes. J Clin Invest 2005; 115: 1111-9. doi: 10.1172/JCI25102 10. 10. Kannel WB. Lipids,diabetes and coronary heart disease. insights from the framingham study. Am Heart J 1985; 110:1100-7. doi: 10.1016/0002-8703(85)90224-8 11. 11. Taskinen MR. Diabetic dyslipidaemia. from basic research to clinical practice. Diabetologia 2003; 46:733-49. doi.org/10.1007/s00125-003-1111-y 12. 12. Solano MP, Goldberg RB. Management of dyslipidemia in diabetes. Cardiol Rev 2006; 14: 125-35. doi: 10.1097/01.crd.0000188034.76283.5e 13. 13. Ishimura S. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One 2013; 8:e81318. doi.org/10.1371/journal.pone.0081318 14. 14. Furuhashi M. Fatty acid binding protein 4 (FABP4). pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin Med Insights Cardiol 2014; 8:23-33. doi: 10.4137/CMC.S17067 15. 15. Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs--mechanisms and therapeutic implications. Nat Rev Endocrinol 2015; 11:592-605. doi: 10.1038/nrendo.2015.122 16. 16. medicine Nlo. rs8192688. dbSNP. 2020. 17. 17. Medrano RFV, de Oliveira CA. Guidelines for the tetra-primer ARMS-PCR technique development. Mol biotech 2014; 56:599-608. doi: 10.1007/s12033-014-9734-4 18. 18. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009; 53: S35-42. doi: 10.1016/j.jacc.2008.09.055 19. 19. Matheus AS. Impact of diabetes on cardiovascular disease. an update. Int J Hypertens 2013; 653789. doi: 10.1155/2013/653789 20. 20. Watts GF, Playford DA. Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus. an hypothesis. Atherosclerosis 1998; 141: 17-30. doi: 10.1016/s0021-9150 (98)00170-1 21. 21. Daousi C. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006; 82:280-4. doi: 10.1136/pmj.2005.039032 22. 22. Senemar S, Edraki MR, Toosi S. Association between type 2 diabetes mellitus, biochemical factors and UCSNP-43 polymorphisms of CALPIN-10 gene in patients with atherosclerosis of coronary artery disease in Southern Iran population. J Cardiovasc Thorac Res 2016; 8:13-9. doi: 10.15171/jcvtr.2016.03 23. 23. Zadhoush F, Sadeghi M, Pourfarzam M. Biochemical changes in blood of type 2 diabetes with and without metabolic syndrome and their association with metabolic syndrome components. J Res Med Sci 2015; 20:763-70. doi: 10.4103/1735-1995.168383 24. 24. Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia 2008. 51: p. 926-940. doi: 10.1007/s00125-008-0954-7 25. 25. Adela R. Serum protein signature of coronary artery disease in type 2 diabetes mellitus. J Transl Med 2019; 17:17. doi.org/10.1186/s12967-018-1755-5 26. 26. Ye X. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardio Diabet 2019; 18:48. doi.org/10.1186/s12933-019-0851-z 27. 27. Kaftan A, Hussain M. Association of Adiponectin Gene Polymorphism rs266729 with Type Two Diabetes Mellitus in Iraqi Population. a pilot Study. Gene 2015; 570. doi: 10.1016/j.gene.2015.06.004 28. 28. Kannel WB. Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study. American Heart J 1985;110:1100-107. doi: 10.1016/0002-8703(85)90224-8 29. 29. Wu Z. Different associations between HDL cholesterol and cardiovascular diseases in people with diabetes mellitus and people without diabetes mellitus. a prospective community-based study. American J Clinical Nutrition 2021; 114:907-13. doi: 10.1093/ajcn/nqab163 30. 30. Mansego ML. Common variants of the liver fatty acid binding protein gene influence the risk of type 2 diabetes and insulin resistance in Spanish population. PLoS One 2012; 7:e31853. doi.org/10.1371/journal.pone.0031853 31. 31. Ibarretxe D. FABP4 plasma concentrations are determined by acquired metabolic derangements rather than genetic determinants. Nutr Metab Cardiovasc Dis 2015; 25:875-80. doi: 10.1016/j.numecd.2015.05.008.
|